

## BIRTHING OF GIANTS: ACCELERATOR PROGRAM

The Birthing of Giants Accelerator Program is chaired by Board of Experts member, Doug Tatum and comprises the total capabilities of the entire Board of Experts. The Accelerator Program is a service provided to Birthing of Giants Fellows at the discretion of the Board of Experts. Any company selected by the Board of Experts will receive individualized advisory support from the Board for the most crucial aspects of company scaling to include:

- Strategy Development & Articulation
- Strategic Partnerships & Capital Market Readiness
- Exit Strategy Positioning

If you are selected by the Board of Experts for the Accelerator Program, you can expect the full advice and support of the Board as you decide how to position your company in the event of a capital raise, whether “Moneymaker” or “Moonshot.” If you think your company is a good fit for Birthing of Giants Accelerator Program, contact us. Of course, we are working with many of you all the time and are excited to see opportunities within your companies that you might not even see.

The participants in the program would be selected on their likelihood of attracting professional investment capital to support their vision and have been members of the Birthing of Giants Community.

### The Birthing of Giants Accelerator Co-Investment Program

Birthing of Giants will make available to its members co-investment opportunities that have been vetted and have committed investment capital by outside capital sources on pari-passu terms at the closing of investment in a Birthing of Giants affiliated opportunity.

**Learn While You Earn:** Co-investors will receive step-by-step insight into deal structure and flow. Like a “teaching hospital,” our Board of Experts will lead co-investors through the process, turning each deal into an educational program, allowing them to begin to see how their own deals will progress through the process.

### Business Rules

Co-investment opportunities are made available only to Birthing of Giants Fellowship Program graduates. Fellows will have access to those rounds at the discretion of Birthing of Giants management.

Investments will be pooled in a separate Special Purpose Vehicle managed by Birthing of Giants and administered by Sydecar [www.sydecar.io](http://www.sydecar.io) All Birthing of Giants Fellows who are interested in participating in those fundraising rounds will be required to do so through the Birthing of Giants Special Purpose Vehicle. Birthing of Giants Fellows may not invest directly into a Birthing of Giants Accelerator company without the permission of Birthing of Giants management. Birthing of Giants will receive a sliding scale of a percentage of profits on exits after investors have received 100% of their capital back. There will be no management fees to investors.

Two recent opportunities have been selected and are actively finalizing investment term sheets which provide co-investment opportunities.

## CO-INVESTMENT PROGRAM CURRENT OFFERINGS: AS OF MAY 2022

1) **Birthing of Giants Member Marcel Botha:** [www.10XBeta.com](http://www.10XBeta.com)


The Company [www.prena.life](http://www.prena.life): Medical Device addressing the worldwide problem of premature birth. The Clinical trial in Britain is underwritten by the British Health Care system and the trial will be managed by 10x Beta that specializes in managing clinical trials for medical devices. 10x Beta will be a new investor. Doug Tatum's Seed Fund TIP-Seed is the largest investor and will invest in the next round. This deal is targeted to close in 60 days. Total raise estimated to be \$750,000 of which \$250,000 has been allocated for the Birthing of Giants Co-Investment Program.

Target for closing: 30 days.

2) **Birthing of Giants Member Evren Ozkaya:** [www.supplychainwizard.com](http://www.supplychainwizard.com)

The new Company (a spin out technology company of Evren's consulting firm) is currently preparing to raise capital. The Board of Experts has recommended, and Evren has hired a highly experienced investment banker as a board member to advise Evren in the fundraising process. The details of the deal will most likely include a \$10 million round from an institutional investor and has had \$500,000 allocated to the Birthing of Giants Co-Investment Program. Evren's new company is a category leader in digital manufacturing in the pharma space with first mover advantage and an impressive client list and a rapidly growing pipeline.

Target for closing: 90 days.

BIRTHING OF GIANTS ACCELERATOR: CO-INVESTMENT PROGRAM		
COMPANY	FELLOW	TIMEFRAME
	<b>MARCEL BOTHA</b> (FELLOW, 2019) <b>10X BETA</b> 10XBETA.COM	<b>MAY-JUNE 2022</b>

Birthing of Giants will make available to its members co-investment opportunities that have been vetted and have committed investment capital by outside capital sources on pari-passu terms at the closing of investment in a Birthing of Giants affiliated opportunity.

Prena ([www.prena.life](http://www.prena.life)): Medical device addressing the worldwide problem of premature birth. The clinical trial in Britain is underwritten by the British Health Care system and the trial will be managed by 10x Beta (Marcel Botha, Fellow, 2019) which specializes in managing clinical trials for medical devices. 10x Beta will be a new investor. Doug Tatum's Seed Fund TIP-Seed is the largest investor and will invest in the next round. This deal is targeted to close in 60 days. Total Raise estimated to be \$750,000 of which \$250,000 has been allocated for the Birthing of Giants Accelerator program.

#### General Information:

- Full corporate name: **Kyndermed Inc. d/b/a Prena**
- Address: 35 N Main Street Ste 200, Jasper, GA 30043
- Website: [www.prena.life](http://www.prena.life)
- Pre-money valuation: \$5,000,000

#### Deal Points:

- Deal is structured as convertible debt
- Total raise estimated to be \$750,000 (of which \$250,000 has been allocated for the Birthing of Giants Accelerator program)
- Interest rate paid on the debt is 8% simple interest and will be accrued
- Repayment at Maturity: In the event of "Qualified Financing", or change or control has occurred 5 years after the issuance you will receive repayment of the principal amount and any accrued but unpaid interest
- Conversion to Equity: Will convert at the price per share implied by a \$5,000,000 pre-conversion valuation of the company

#### Learn While You Earn:

- Co-investors will receive step-by-step insight into the Prena deal structure and flow
- Focus on convertible debt
- Focus on short-run product development and new product trials
- Led by Doug Tatum